Search | Clinical Trials Finder

Conditions: Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
Interventions: Radiation Therapy Boost, Pembrolizumab, Paclitaxel, Carboplatin, Cyclophosphamide, Doxorubicin, Capecitabine; Radiation · Drug
Lead sponsor: Laura M. Spring, MD; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 6 more

Conditions: HER2-positive Metastatic Breast Cancer
Interventions: CE-10-IVD; Diagnostic Test
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 37
States / cities: San Francisco, California • Derby, Connecticut • Fairfield, Connecticut + 27 more

Conditions: Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 53
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 46 more

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions: Anastrozole, Letrozole, Exemestane, Tamoxifen, Mammogram, Magnetic Resonance Imaging, Dual X-ray Absorptiometry, Biospecimen Collection, Questionnaire Administration; Drug · Procedure · Biological + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 729
States / cities: Anchorage, Alaska • Gilbert, Arizona • Goodyear, Arizona + 560 more

Conditions: Cancers With HER2 Expression
Interventions: BAY2701439; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more

Conditions: HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal, Stage 0 Breast Cancer, Stage IA Breast Cancer
Interventions: Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Questionnaire Administration, Tamoxifen Citrate, Toremifene Citrate; Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 60 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer
Interventions: AST-301(pNGVL3-hICD), rhuGM-CSF, Placebo, Pembrolizumab, Capecitabine; Biological · Drug
Lead sponsor: Aston Sci. Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Chandler, Arizona • La Jolla, California • Tampa, Florida + 7 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic HER2-Low Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma, Unresectable HER2-Low Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma, Unresectable Hormone Receptor-Positive Breast Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Triple-Negative Breast Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan, Pidnarulex, Radiologic Imaging Procedure, Trastuzumab Deruxtecan; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer
Interventions: Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin, Gemcitabine, Paclitaxel, Nab-paclitaxel; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 38
States / cities: Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 31 more

Conditions: HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions: Cyclophosphamide, Docetaxel, Doxorubicin, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Trastuzumab; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 3,270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2025
U.S. locations: 1259
States / cities: Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 797 more

Conditions: Breast Cancer Metastatic
Interventions: Zenocutuzumab, Trastuzumab, Vinorelbine, Endocrine therapy; Drug
Lead sponsor: Merus B.V.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Los Angeles, California • Kansas City, Kansas • Nashville, Tennessee

Conditions: Triple Negative Breast Cancer, HER2-negative Breast Cancer
Interventions: HER2 - primed Dendritic cells, HER3 - primed Dendritic cells; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: Herceptin, NeuVax vaccine, GM-CSF; Drug
Lead sponsor: George E. Peoples; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 29
States / cities: Beverly Hills, California • Santa Monica, California • Santa Rosa, California + 22 more

Conditions: Breast Cancer
Interventions: Everolimus; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Breast Cancer
Interventions: BB-1701; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 27
States / cities: Los Alamitos, California • Los Angeles, California • San Francisco, California + 22 more

Conditions: Breast Cancer
Interventions: Low dose FRα vaccine, Cyclophosphamide, High dose FRα vaccine; Biological · Drug
Lead sponsor: Marker Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 11
States / cities: Tampa, Florida • Westwood, Kansas • Baltimore, Maryland + 7 more

Conditions: Breast Cancer
Interventions: Trastuzumab deruxtecan, Valemetostat; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL, L-MYC and N-MYC Amplified Solid Tumors, NSCLC With High or Low L-MYC or N-MYC Expression, HR-positive, HER2-negative Breast Cancer, Prostate Cancer
Interventions: Oral MRT-2359; Drug
Lead sponsor: Monte Rosa Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 13 more

Conditions: HER2 Positive Breast Cancer
Interventions: tucatinib, capecitabine, trastuzumab, placebo; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 81
States / cities: Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 66 more

Conditions: Breast Carcinoma
Interventions: eftilagimod alpha, Paclitaxel, placebo; Biological · Drug · Other
Lead sponsor: Immutep S.A.S.; Industry
Eligibility: 18 Years and older
Enrollment: 849 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Whittier, California • Washington D.C., District of Columbia • Rock Hill, South Carolina + 1 more

Conditions: Breast Cancer
Interventions: None (Observational study); Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 798 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Interventions: AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab; Drug
Lead sponsor: Aminex Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 12
States / cities: Los Angeles, California • Englewood, Colorado • Detroit, Michigan + 8 more

Conditions: Breast Neoplasms, Breast Cancer
Interventions: Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Cyclophosphamide, Capecitabine, Olaparib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 8
States / cities: Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
Interventions: Anastrozole, Biospecimen Collection, Bone Scan, Chemotherapy, Computed Tomography, Exemestane, Letrozole, Oncotype DX Breast Cancer Assay, Positron Emission Tomography, Ribociclib Succinate; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,978 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 14
States / cities: Bloomington, Illinois • Canton, Illinois • Carthage, Illinois + 11 more

Search by objective public record fields.

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer

Study of Oral MRT-2359 in Selected Cancer Patients

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial